We are live on ! Find out more
ITCI

Intra-Cellular Therapies Inc.
ITCI

Delisted

ITCI was delisted on the 1st of April, 2025.

Back to rankings

4 hedge funds and large institutions have $4.15M invested in Intra-Cellular Therapies Inc. in 2025 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 389 closing their positions.

New
Increased
Maintained
Reduced
Closed

99% less funds holding

Funds holding: 395 → 4 (-391)

100% less capital invested

Capital invested by funds: $13.6B → $4.15M (-$13.6B)

100% less funds holding in top 10

Funds holding in top 10: 52 → 0 (-52)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 389

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
4
Holders Change
-391
Holders Change %
-98.99%
% of All Funds
0.05%
Holding in Top 10
–
Holding in Top 10 Change
-52
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
2
Closed
389
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$1.26B
2
BlackRock
BlackRock
New York
-$1.15B
3
PCM
Pentwater Capital Management
Florida
-$685M
4
HI
HBK Investments
Texas
-$578M
5
Norges Bank
Norges Bank
Norway
-$472M
Name Holding Trade Value Shares
Change 		Change in
Stake
DekaBank Deutsche Girozentrale
1
DekaBank Deutsche Girozentrale
Germany
$4.09M – – –
Osaic Holdings
2
Osaic Holdings
Arizona
$60.1K -$29.1K -221 -22%
KIM
3
Kestra Investment Management
Texas
$5.8K – – –
HNB
4
Huntington National Bank
Ohio
$2.54K -$32K -243 -100%
Vanguard Group
5
Vanguard Group
Pennsylvania
– -$1.26B -9,519,968 Closed
BlackRock
6
BlackRock
New York
– -$1.15B -8,754,966 Closed
PCM
7
Pentwater Capital Management
Florida
– -$685M -5,190,000 Closed
HI
8
HBK Investments
Texas
– -$578M -4,385,000 Closed
Norges Bank
9
Norges Bank
Norway
– -$472M -3,579,571 Closed
DKCM
10
Davidson Kempner Capital Management
New York
– -$460M -3,485,058 Closed
UOC
11
UBS O'Connor
Illinois
– -$408M -3,091,133 Closed
FCM
12
Farallon Capital Management
California
– -$403M -3,055,000 Closed
Fidelity Investments
13
Fidelity Investments
Massachusetts
– -$351M -2,662,273 Closed
Balyasny Asset Management
14
Balyasny Asset Management
Illinois
– -$298M -2,257,912 Closed
Citadel Advisors
15
Citadel Advisors
Florida
– -$295M -2,237,131 Closed
DTC
16
Deep Track Capital
Connecticut
– -$264M -2,000,000 Closed
Geode Capital Management
17
Geode Capital Management
Massachusetts
– -$242M -1,831,951 Closed
Bank of America
18
Bank of America
North Carolina
– -$239M -1,815,287 Closed
State Street
19
State Street
Massachusetts
– -$235M -1,781,316 Closed
WAM
20
Weiss Asset Management
Massachusetts
– -$216M -1,640,029 Closed
UBS Group
21
UBS Group
Switzerland
– -$210M -1,590,345 Closed
GCL
22
Glazer Capital LLC
New York
– -$208M -1,579,685 Closed
Goldman Sachs
23
Goldman Sachs
New York
– -$194M -1,473,764 Closed
Morgan Stanley
24
Morgan Stanley
New York
– -$185M -1,403,399 Closed
Voloridge Investment Management
25
Voloridge Investment Management
Florida
– -$144M -1,093,738 Closed
1
2 3 4 5

ITCI Hedge Fund Activity: Q2 2025 in Review

4 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q2 2025, worth a combined $4.15M — down 100% from $13.6B a quarter earlier.

Sellers outnumbered buyers: 389 funds closed out of ITCI and 0 opened new positions — a net loss of 389 holders — while 2 trimmed existing stakes and 0 added.

The largest seller was Vanguard Group, exiting entirely with an estimated $1.26B sold.

  • 4 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q2 2025, down from 395 in Q1 2025.
  • Funds reported $4.15M of Intra-Cellular Therapies Inc. stock for Q2 2025, down 100% quarter-over-quarter.
  • 0 funds opened new Intra-Cellular Therapies Inc. positions in Q2 2025 and 389 closed out, a net change of -389 holders.
  • The largest Intra-Cellular Therapies Inc. seller in Q2 2025 was Vanguard Group, an estimated $1.26B sold.

Based on aggregated 13F filings for Q2 2025.